Australian market update: Telix Pharmaceuticals shares surge

Telix Pharmaceuticals Ltd has seen its shares nearly double since early February, reaching $16.44 in recent trading. The company specializes in radiopharmaceuticals, combining radioactive isotopes with targeted therapies for cancer detection and treatment. Recent financial reports show a 22% year-on-year revenue increase to US$477 million, with adjusted EBITDA rising 146% to US$52 million. Telix has reaffirmed its FY26 revenue guidance of over US$1 billion.

In other Australian market news, Telstra Group Ltd has experienced a 2.3% decline in share price since the start of 2025. Meanwhile, Mineral Resources Ltd shares are currently approximately 85.6% above their 52-week low. Mineral Resources remains focused on lithium and iron ore extraction in Western Australia while providing engineering services through its subsidiary, CSI Mining Services.